Jeff Bluestone steps from bench to bedside to chief academic officer. [An interview with Jeff Blustone].
نویسنده
چکیده
The Journal of Clinical Investigation http://www.jci.org Volume 120 Number 5 May 201
منابع مشابه
Serious Ideas for Serious Investors
Active Vs. Index: The Liquid Alternative Strategies Game Heats Up Joanne Hill Hedge Fund Indexation And Replication Marc Freed Building An LBO Index Jeff Hooke and Ted Barnhill The Half-Life Of Smart Beta Elisabeth Kashner Plus an interview with the CIO of the LSU Foundation, Blitzer on the importance of liquidity, Edhec’s Amenc and Goltz on smart-beta criticisms, Ossiam’s Rulik on rebalancing ...
متن کاملDEFCON Behind the Scene
Jeff Moss took the audience on a behind-the-scenes look at cybersecurity policy and practice, starting from the origins of DEFCON, and continuing on to present day Washington, DC policy-making as ICANN’s chief security officer. Two decades ago, when the first DEFCON was taking shape, part of the goal was to get as many computer security-focused individuals in one place in order to encourage the...
متن کاملTranslational Antidote Research: A Bedside to Bench Tale
Although antidote development should proceed in an orderly fashion from observation, to experimental and safety studies, to clinical trials, this sequence is not always precisely followed. The development of fomepizole as an antidote for toxic alcohol and glycol poisoning is an example of how this may not be the case. Interest in the development of fomepizole was spurred in the 1960s. Shortly t...
متن کاملActive Leadership Can Promote Leadership Effectiveness in Healthcare Organizations
Background and Objectives: The healthcare organization are often fail to realize their strategic goals due to the lack of effective leadership. To address this efficiency, factors can possibly influence the management performance should be identified. Thus, the purpose of this study was to evaluate hospital managers’ leadership style and explore the relationship between leadership style in hosp...
متن کاملPromising role for Gc-MAF in cancer immunotherapy: from bench to bedside
Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of clinical investigation
دوره 120 5 شماره
صفحات -
تاریخ انتشار 2010